JP2007535473A - Chlamydiatrachomatisに対する免疫原性組成物 - Google Patents
Chlamydiatrachomatisに対する免疫原性組成物 Download PDFInfo
- Publication number
- JP2007535473A JP2007535473A JP2006517684A JP2006517684A JP2007535473A JP 2007535473 A JP2007535473 A JP 2007535473A JP 2006517684 A JP2006517684 A JP 2006517684A JP 2006517684 A JP2006517684 A JP 2006517684A JP 2007535473 A JP2007535473 A JP 2007535473A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- protein
- antigen
- antigens
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000606153 Chlamydia trachomatis Species 0.000 title claims abstract description 267
- 229940038705 chlamydia trachomatis Drugs 0.000 title claims abstract description 262
- 239000000203 mixture Substances 0.000 title claims abstract description 216
- 230000002163 immunogen Effects 0.000 title claims description 68
- 108091007433 antigens Proteins 0.000 claims abstract description 515
- 102000036639 antigens Human genes 0.000 claims abstract description 515
- 239000000427 antigen Substances 0.000 claims abstract description 514
- 239000002671 adjuvant Substances 0.000 claims abstract description 102
- 101710098399 Outer membrane protein YopN Proteins 0.000 claims abstract description 49
- 229960005486 vaccine Drugs 0.000 claims abstract description 47
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 31
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 18
- 239000011707 mineral Substances 0.000 claims abstract description 18
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 208000019802 Sexually transmitted disease Diseases 0.000 claims abstract description 11
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 claims abstract description 8
- 102100021119 Serine protease HTRA1 Human genes 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 333
- 108090000623 proteins and genes Proteins 0.000 claims description 251
- 230000003472 neutralizing effect Effects 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 27
- 230000028993 immune response Effects 0.000 claims description 26
- 239000002955 immunomodulating agent Substances 0.000 claims description 17
- 229940121354 immunomodulator Drugs 0.000 claims description 16
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims description 13
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims description 13
- 230000029662 T-helper 1 type immune response Effects 0.000 claims description 13
- 230000029069 type 2 immune response Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 206010061041 Chlamydial infection Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 description 329
- 239000012634 fragment Substances 0.000 description 179
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 140
- 235000001014 amino acid Nutrition 0.000 description 123
- 150000001413 amino acids Chemical class 0.000 description 121
- 241000699670 Mus sp. Species 0.000 description 79
- 241000606161 Chlamydia Species 0.000 description 68
- 108010076504 Protein Sorting Signals Proteins 0.000 description 66
- 108090000765 processed proteins & peptides Proteins 0.000 description 64
- 125000003275 alpha amino acid group Chemical group 0.000 description 63
- 230000003053 immunization Effects 0.000 description 58
- 102000004196 processed proteins & peptides Human genes 0.000 description 55
- 238000002649 immunization Methods 0.000 description 54
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 52
- 208000015181 infectious disease Diseases 0.000 description 52
- 229920001184 polypeptide Polymers 0.000 description 51
- 230000001086 cytosolic effect Effects 0.000 description 50
- 229940037003 alum Drugs 0.000 description 43
- 210000002966 serum Anatomy 0.000 description 42
- 238000003556 assay Methods 0.000 description 37
- 238000006386 neutralization reaction Methods 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 31
- 238000000338 in vitro Methods 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 101710164702 Major outer membrane protein Proteins 0.000 description 26
- 238000001262 western blot Methods 0.000 description 24
- -1 alum Chemical compound 0.000 description 23
- 101000575173 Homo sapiens 60S ribosomal protein L12 Proteins 0.000 description 21
- 101000659995 Homo sapiens Ribosomal L1 domain-containing protein 1 Proteins 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 21
- 102100025643 60S ribosomal protein L12 Human genes 0.000 description 20
- 239000013641 positive control Substances 0.000 description 20
- 241000588724 Escherichia coli Species 0.000 description 19
- 230000001681 protective effect Effects 0.000 description 19
- 229930182490 saponin Natural products 0.000 description 19
- 150000007949 saponins Chemical class 0.000 description 19
- 235000017709 saponins Nutrition 0.000 description 19
- 208000007190 Chlamydia Infections Diseases 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 230000036039 immunity Effects 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 18
- 102000039446 nucleic acids Human genes 0.000 description 18
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 15
- 239000013642 negative control Substances 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 102000037865 fusion proteins Human genes 0.000 description 14
- 108020001507 fusion proteins Proteins 0.000 description 14
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 12
- 239000003053 toxin Substances 0.000 description 12
- 231100000765 toxin Toxicity 0.000 description 12
- 108700012359 toxins Proteins 0.000 description 12
- 108010070675 Glutathione transferase Proteins 0.000 description 11
- 102000005720 Glutathione transferase Human genes 0.000 description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 11
- 101150077194 CAP1 gene Proteins 0.000 description 10
- 206010061598 Immunodeficiency Diseases 0.000 description 10
- 208000029462 Immunodeficiency disease Diseases 0.000 description 10
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 230000000890 antigenic effect Effects 0.000 description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 10
- 230000007813 immunodeficiency Effects 0.000 description 10
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 10
- 229960005225 mifamurtide Drugs 0.000 description 10
- 102100032534 Adenosine kinase Human genes 0.000 description 9
- 108020000543 Adenylate kinase Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000701806 Human papillomavirus Species 0.000 description 9
- 102000005741 Metalloproteases Human genes 0.000 description 9
- 108010006035 Metalloproteases Proteins 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004201 immune sera Anatomy 0.000 description 9
- 229940042743 immune sera Drugs 0.000 description 9
- 230000002584 immunomodulator Effects 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 8
- 102000006303 Chaperonin 60 Human genes 0.000 description 8
- 108010058432 Chaperonin 60 Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 108090000553 Phospholipase D Proteins 0.000 description 8
- 102000011420 Phospholipase D Human genes 0.000 description 8
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 8
- 230000008827 biological function Effects 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 230000003308 immunostimulating effect Effects 0.000 description 8
- 210000003000 inclusion body Anatomy 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 8
- 231100000252 nontoxic Toxicity 0.000 description 8
- 230000003000 nontoxic effect Effects 0.000 description 8
- 102000022744 oligopeptide binding proteins Human genes 0.000 description 8
- 108091013547 oligopeptide binding proteins Proteins 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 229940031439 squalene Drugs 0.000 description 8
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 101100054302 Arabidopsis thaliana ABCB3 gene Proteins 0.000 description 6
- 101100113915 Arabidopsis thaliana CLS gene Proteins 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 206010048461 Genital infection Diseases 0.000 description 6
- 201000005702 Pertussis Diseases 0.000 description 6
- 101150063830 abcB4 gene Proteins 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 239000007764 o/w emulsion Substances 0.000 description 6
- 101150047779 ompB gene Proteins 0.000 description 6
- 101150031507 porB gene Proteins 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000000277 virosome Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 5
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 5
- 101100243724 Caenorhabditis elegans pgp-3 gene Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 5
- 108091006054 His-tagged proteins Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 101710116435 Outer membrane protein Proteins 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 101150059608 pmpE gene Proteins 0.000 description 5
- 101150033274 pmpI gene Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241001647372 Chlamydia pneumoniae Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 108010013381 Porins Proteins 0.000 description 4
- 102000017033 Porins Human genes 0.000 description 4
- 108091027981 Response element Proteins 0.000 description 4
- 206010043376 Tetanus Diseases 0.000 description 4
- 108060000200 adenylate cyclase Proteins 0.000 description 4
- 102000030621 adenylate cyclase Human genes 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 206010013023 diphtheria Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 230000000521 hyperimmunizing effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000016379 mucosal immune response Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 101100327692 Caenorhabditis elegans hsp-60 gene Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 3
- 241000606069 Chlamydiaceae Species 0.000 description 3
- 241000498849 Chlamydiales Species 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 101000597425 Homo sapiens Nuclear RNA export factor 2 Proteins 0.000 description 3
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 101100521429 Lactococcus lactis subsp. lactis (strain IL1403) prsA gene Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 102100035403 Nuclear RNA export factor 2 Human genes 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 3
- 102100037599 SPARC Human genes 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000227 bioadhesive Substances 0.000 description 3
- 210000004520 cell wall skeleton Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 229940063223 depo-provera Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 3
- 238000012405 in silico analysis Methods 0.000 description 3
- 238000000126 in silico method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000003232 mucoadhesive effect Effects 0.000 description 3
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 3
- 101150087557 omcB gene Proteins 0.000 description 3
- 101150115693 ompA gene Proteins 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 101150010607 pmpA gene Proteins 0.000 description 3
- 229920000056 polyoxyethylene ether Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 210000005000 reproductive tract Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241001185363 Chlamydiae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100038385 Coiled-coil domain-containing protein R3HCC1L Human genes 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000672609 Escherichia coli BL21 Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108091006057 GST-tagged proteins Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710194807 Protective antigen Proteins 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 241000219287 Saponaria Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 241000589884 Treponema pallidum Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000012382 advanced drug delivery Methods 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 101150042295 arfA gene Proteins 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 101150008740 cpg-1 gene Proteins 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 101150052825 dnaK gene Proteins 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000011554 guinea pig model Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000012750 in vivo screening Methods 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 244000000056 intracellular parasite Species 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940066429 octoxynol Drugs 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229940066827 pertussis vaccine Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 101150106828 pmpD gene Proteins 0.000 description 2
- 101150095517 pmpH gene Proteins 0.000 description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 description 2
- 108010094020 polyglycine Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 1
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 101001051297 Aspergillus oryzae (strain ATCC 42149 / RIB 40) Leucine aminopeptidase A Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- GWTIREPSNMQXFT-ZOFDZZIGSA-N C[C@H]([C@@H](C(=O)N(C(=O)C)[C@@](CCC(=O)O)(C1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O[C@H](C)C(=O)O)N)C(=O)N)N)O Chemical compound C[C@H]([C@@H](C(=O)N(C(=O)C)[C@@](CCC(=O)O)(C1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O[C@H](C)C(=O)O)N)C(=O)N)N)O GWTIREPSNMQXFT-ZOFDZZIGSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108050001186 Chaperonin Cpn60 Proteins 0.000 description 1
- 102000052603 Chaperonins Human genes 0.000 description 1
- 241000736839 Chara Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108700013373 Chlamydia trachomatis Cap1 Proteins 0.000 description 1
- 108010039166 Chlamydia trachomatis protein 60K Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 1
- 101000619151 Dickeya chrysanthemi Serralysin B Proteins 0.000 description 1
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108010012253 E coli heat-labile enterotoxin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241001316290 Gypsophila Species 0.000 description 1
- 240000003824 Gypsophila paniculata Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 101150031823 HSP70 gene Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 108010072039 Histidine kinase Proteins 0.000 description 1
- 101000743767 Homo sapiens Coiled-coil domain-containing protein R3HCC1L Proteins 0.000 description 1
- 101000637373 Homo sapiens Sperm acrosome membrane-associated protein 3 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 239000006391 Luria-Bertani Medium Substances 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 102100033468 Lysozyme C Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588649 Neisseria lactamica Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 101100278084 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) dnaK1 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710178084 Probable outer membrane protein PmpD Proteins 0.000 description 1
- 101710178085 Probable outer membrane protein PmpE Proteins 0.000 description 1
- 101710188053 Protein D Proteins 0.000 description 1
- 208000006930 Pseudomyxoma Peritonei Diseases 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 101710132893 Resolvase Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 241000319353 Simkaniaceae Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 241000362909 Smilax <beetle> Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 102100032147 Sperm acrosome membrane-associated protein 3 Human genes 0.000 description 1
- 101100117145 Synechocystis sp. (strain PCC 6803 / Kazusa) dnaK2 gene Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 108010031127 Transferrin-Binding Protein B Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108010074827 UDP-N-acetylglucosamine-N-acetylmuramyl-(pentapeptide)pyrophosphoryl-undecaprenol N-acetylglucosamine transferase Proteins 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940124832 acellular pertussis vaccine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 102000031645 arginine binding proteins Human genes 0.000 description 1
- 108091009880 arginine binding proteins Proteins 0.000 description 1
- 101150002692 artJ gene Proteins 0.000 description 1
- 208000016063 arterial thoracic outlet syndrome Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000000902 chlamydia Diseases 0.000 description 1
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010961 commercial manufacture process Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001424 field-emission electron microscopy Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- HOPZBJPSUKPLDT-UHFFFAOYSA-N imidazo[4,5-h]quinolin-2-one Chemical class C1=CN=C2C3=NC(=O)N=C3C=CC2=C1 HOPZBJPSUKPLDT-UHFFFAOYSA-N 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 238000010397 one-hybrid screening Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 101150067195 pmpB gene Proteins 0.000 description 1
- 101150050161 pmpC gene Proteins 0.000 description 1
- 101150116202 pmpF gene Proteins 0.000 description 1
- 101150053615 pmpG gene Proteins 0.000 description 1
- 229940124733 pneumococcal vaccine Drugs 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本出願は、引用により、2003年6月26日に出願された英国特許出願第0315020.8;2003年8月25日に出願された米国仮特許出願シリアル番号60/497,649;2004年2月2日に出願された英国特許出願第0402236.4;および2004年6月1日に出願された米国仮特許出願シリアル番号60/576,375の全体を一体化させる。
本発明の分野は免疫学およびワクチン学である。特に、Clamydia trachomatis由来の抗原およびその免疫化におけるその使用に関連する。
Clamydiae(クラミジア門)は真核細胞の偏性細胞内寄生体であり、流行性行為感染症および多様な疾病症候群の原因菌である。特に真性細菌系統枝の位置にあり、他のどの既知生物体とも関連しない。
C.trachomatisゲノムについて以前に記載された〜900タンパク質(例えば、Stethens et al.(1998) Science 282:754−759)内で、本発明者らは、特に、組み合せて用いた場合に、免疫化目的で特に適した5つのChlamydia trachomatis抗原の群を発見した。本発明は、従って、Chlamydia trachomatis抗原の組合せを含む組成物を提供し、該組合せは、第一の抗原群の2、3、4または全ての5つのChlamydia trachomatis抗原よりなり、該第一の抗原群は(1)PepA(CT045);(2)LcrE(CT089);(3)ArtJ(CT381);(4)DnaK(CT396);および(5)CT398よりなる。これらの抗原は本明細書中においては「第一の抗原群」という。好ましくは、該組合せはLcrE(CT089)を含む。
前記したように、本発明は、Chlamydia trachomatis抗原の組合せを含む組成物を提供し、ここに、該組合せは、出願人らが、特に、組み合わせて用いた場合に免疫化目的に特に適したものと同定した抗原の群から選択することができる。1つの具体例において、本発明はChlamydia trachomatis抗原の組み合わせを含む組成物を提供し、該組合せは第一の抗原群の2、3、4または全ての5つのChlamydia trachomatis抗原よりなり、該第一の抗原は(1)PepA(CT045);(2)LcrE(CT089);(3)ArtJ(CT381);(4)DnaK(CT396);および(5)CT398よりなる。これらの抗原は本明細書中においては「第一の抗原群」という。
本発明で用いるChlamydia trachomatis抗原は個々の別々のポリペプチドとして組成物に存在させることができる。一般に、本発明の組換え融合タンパク質がGST−融合タンパク質および/またはHis−タグド融合タンパク質として調整される。
本発明の好ましいポリペプチドは、C.trachomatis血液型亜型Dにおいて、または疫学的に流行している血清型の1以上で見出されるアミノ酸配列を含む。
本発明のポリペプチドの発現はクラミジアで起こり得るが、本発明は、好ましくは、異種宿主を利用する。異種宿主は原核生物(例えば、細菌)または真核生物であり得る。それは好ましくはE.Coliであるが、他の適当な宿主はBacillus subtilis、Vibrio cholerae、Salmonella typhi、Salmonella typhimurium、Neisseria lactamica、Neisseria cinerea、Mycobacteria(例えば、M.tubarculosis)、酵母等を含む。
本発明の組成物は、好ましくは、免疫原性組成物であって、より好ましくはワクチン組成物である。組成物のpHは好ましくは6および8の間であり、好ましくは約7である。該pHは緩衝液の使用によって維持することができる。該組成物は滅菌しおよび/またはパイロジェン−フリーであり得る。組成物はヒトに対して等張であり得る。
本発明の組成物は、典型的には、前記した成分に加えて、組成物を受容する個体に有害な抗体の生産をそれ自身誘導しないいずれかの担体を含む1以上の「医薬上許容される担体」を含む。適当な担体は、典型的には、タンパク質、多糖、ポリ乳酸、ポリグリコール酸、ポリマーアミノ酸、アミノ酸コポリマー、(油液滴またはリポソームのような)脂質凝集体のような大きなゆっくりと代謝されるマクロ分子である。そのような担体は当業者によく知られている。ワクチンは水、生理食塩水、グリセロールなどのような希釈剤も含むことができる。加えて、湿潤剤、または乳化剤、pH緩衝物質のような補助的物質を存在させることができる。医薬上許容される賦形剤の徹底的な議論はGennaro(2000) Remington:THe Science and Practice of Pharmacy.第20版,ISBN:0683306472で入手できる。
本発明のワクチンは他の免疫調節剤と組み合わせて投与することができる。特に、組成物は、通常、アジュバントを含む。本発明で用いられるアジュバントは、限定されるものではないが、以下の1以上を含む。
本発明におけるアジュバントとして用いるのに適したミネラル含有組成物はアルミニウム塩およびカルシウム塩のようなミネラル塩を含む。本発明は水酸化物(例えば、オキシ水酸化物)、リン酸塩(例えば、ヒドロキシリン酸塩、オルトリン酸塩)、硫酸塩(例えば、Vaccine Design...(1995) Powell & Newman.ISBN:030644867X.Plenum.の第8章および第9章参照)、異なるミネラル化合物の混合物(例えば、所望により過剰のリン酸塩と一緒にしたリン酸塩および水酸化物アジュバントの混合物)のような塩を含み、該化合物はいずれかの適当な形態(例えば、ゲル、結晶、アモルファスなど)を取り、塩への吸着が好ましい。ミネラル含有組成物は金属塩の粒子として処方することもできる(WO 00/23105)。
本発明におけるアジュバントとして用いるのに適した油−エマルジョン組成物はMF59(ミクロフルイダイザーを用いてサブミクロン粒子に処方された5%スクアレン、0.5%Tween 80および0.5% Span 85)のようなスクアレン水エマルジョンを含む。WO 90/14837参照。また、Frey et al.,「Comparison of the safety, tolerability, and immunogenicity of a MF59−adjuvanted influenza vaccine and a non−adjuvanted influenza vaccine in non−elderly adults」,Vaccine (2003) 21:4234−4237参照。MF59はFLUADTMインフルエンザウイルス三価サブユニットワクチンとして用いられる。
サポニン処方も本発明においてアジュバントとして用いることもできる。サポニンは、広い範囲の植物種の樹皮、葉、幹、芽および花でさえで見出されるストールグリコシドおよびトリテルペノイドグリコシドの異種群である。Quillaia saponaria Molina樹木の樹皮からのサポニンはアジュバントとして広く研究されてきた。サポニンはSmilax ornata(サルサパリラ)、Gypsophilla paniculata(ブライデスベール)、Saponaria officianalis(カスミソウ)から商業的に得ることもできる。サポニンアジュバント処方はQS21のような精製された処方、ならびにISCOMのような脂質処方を含む。
ビロソームおよびウイルス様粒子(VLP)も本発明でアジュバントとして用いることができる。これらの構造は、一般には、所望によりリン脂質に含まれるまたはそれで処方されたウイルスからの1以上のタンパク質を含有する。それらは、一般には、非−病原体、非−複製性であって、一般には、天然ウイルスゲノムのいずれも含有しない。該ウイルスタンパク質は組換えにより生産することができ、あるいは全ウイルスから単離することができる。ビロソームまたはVLPで用いるのに適したこれらのウイルスタンパク質は(HAまたはNAのような)インフルエンザウイルス、(コアまたはキャプシドタンパク質のような)B型肝炎ウイルス、E型肝炎ウイルス、麻疹ウイルス、シンドビスウイルス、ロタウイルス、***病ウイルス、レトロウイルス、ノルウォークウイルス、ヒトパピローマウイルス、HIV、RNA−ファージ、(コートタンパク質のような)Qβ−ファージ、GA−ファージ、fr−ファージ、AP205ファージ、および(レトロトランスポゾンTyタンパク質p1のような)Tyに由来するタンパク質を含む。VLPはWO 03/024480、WO 03/024481、およびNiikura et al.,「Chimeric Recombinant Hepatitis E Virus−Like Particles as an Orall Vaccine Vehecle Presenting Foreign Epitopes」, Virology (2002) 293:273−280;Lenz et al.,「Papillomavirus−Like Particles Induce Accute Activation of Dendritic Cells」, Journal of Immunology (2001) 5246−5355;Pinto, et al.「Cellular Immune Responses to Human Papillomavirus (HPV)−16 L1 Healthy Volanteers Immunized with Recombinant HPV−16 L1 Virus−Like Particles」, Journal of Infectious Diseases (2003) 188:327−338;およびGerber et al.,「Human Papillomavirus−Like Particles Are Effcient Orall Immunogens when Coadministered with Escherichia coli Heat−Labile Entertoxin Mutant R192G or CpG」, Journal of Virology (2001) 75(10):4752−4760にさらに議論されている。ビロソームは、例えば、Gluck et al.,「New Technology Platforms in the Development of Vaccines for the Future」, Vaccine (2002) 20:B10−B16にさらに議論されている。免疫増強復元インフルエンザビロソーム(IRIV)は鼻腔内三価INFLEXALTM製品{Mischler & Metcalfe(2002)Vaccine 20 Suppl 5:B17−23}およびINFLUVAC PLUSTM製品においてサブユニット抗原送達系として用いられる。
本発明で用いるのに適したアジュバントは以下のような細菌または微生物誘導体を含む。
そのような誘導体はモノホスホリル脂質A(MPL)および3−O−脱アセチル化MPL(3dMPL)を含む。3dMPLは4、5または6のアセチル化鎖を持つ3つの脱−O−アセチル化モノホスホリル脂質Aの混合物である。3つの脱−O−アセチル化モノホスホリル脂質Aの好ましい「小さな粒子」はEP 0 689 454に開示されている。3dMPLのそのような「小さな粒子」は、0.22ミクロンの膜を通って滅菌濾過されるのに十分に小さい(EP 0 689 454参照)。他の非−毒性LPS誘導体はアミノアルキルグルコサミニドホスフェート誘導体、例えば、RC−529のようなモノホスホリル脂質Aミミックを含む。Johnson et al.(1999) Bioorg Med Chem Lett 9:2273−2278参照。
脂質A誘導体はOM−174のようなEscherichia coliからの脂質Aの誘導体を含む。OM−174は、例えば、Meraldi et al.,「OM−174,a New Adjuvant with a Potential for Human Youth, Induces a Protective Response with Administered with the Synthetic C−Terminal Fragment 242−310 from the circumporozoite protein of Plasmodium barghei」, Vaccine (2003) 21:2485−2491;およびPajak, et al.,「The Adjuvant OM−174 induces both the migration and maturation of murine dendritic cells in vivo」, Vaccine (2003) 21:836−842に記載されている。
本発明でアジュバントとして用いるのに適した免疫刺激オリゴヌクレオチドはGpGモチーフを含有するヌクレオチド配列を含む(未メチル化シトシン、続いてグアニンを含有し、リン酸結合によって結合された配列)。回文またはポリ(dG)配列を含有する細菌二本鎖RNAまたはオリゴヌクレオチドも免疫刺激性であることが示されている。
細菌ADP−リボシル化トキシンおよびその解毒された誘導体は本発明でアジュバントとして用いることができる。好ましくは、該タンパク質はE. coli(すなわち、E.coli加熱不安定エンテロトキシン「LT」)、コレラ(「CT」)、または百日咳(「PT」)に由来する。粘膜アジュバントとしての解毒されたADP−リボシル化トキシンの使用はWO 95/17211に記載されており、WO 98/42375に非経口アジュバントとして記載されている。好ましくは、該アジュバントはLT−K63、LT−R72およびLTR192Gのような解毒されたLT突然変異体である。ADP−リボシル化トキシンおよびその解毒誘導体、特に、LT−K63およびLT−R72のアジュバントとしての使用は、その各々を、ここに引用してその全体を具体例に一体化させる以下の文献で見出すことができる:Beignon, et al.,「The LTR72 Mutant of Heat−Labile Entertoxin of Escherichia coli Enhances the Ability of peptide antigens to Elicit CD4+ T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin」, Infection and Immunity (2002)]70(6):3012−3019;Pizza, et al.,「Mucosal vaccines:non toxic derivatives of LT and CT as mucosal adjuvants」, Vaccine (2001) 19:2534−2541;Pizza, et al.,「LTK63 and LTR72, two mucosal adjuvants ready for clinical trials」 Int.J.Med.Microbiol (2000) 290(4−5):455−461;Scharton−Kersten et al.,「Transcutaneous Immunization with Bacterial ADP−Ribosylating Exotoxins, Subunits and Unrelated Adjuvants」, Infection and Immunity (2000) 68(9):5306−5313;Ryan et al.,「Mutants of Escherichia coli Heat−Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Derivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells」 Infection and Immunity (1999) 67(12):6270−6280;Partidos et al.,「Heat−labile entertoxin of Escherichia coli and its cyto−directed mutant LTK63 enhance the proliferative and cytotoxic T−cell responses to intranasally co−immunized synthetic peptides」, Immunol.Lett.(1999) 67(3)209−216;Peppoloni et al.,「Mutants of the Escherichia coli heat−labile entertoxin as safe and strong adjuvants for intranasal derivery of vaccines」, Vaccines (2003) 2(2):285−293;およびPine et al.,(2002)「Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile entertoxin from Escherichia coli (LTK63)」 J. Control Release (2002) 85(1−3):263−270。アミノ酸置換についての多数の文献は、好ましくは、ここに引用してその全体を特別に援用するDomenighini et al.,Mol.Microbiol (1995) 15(6):1165−1167に記載されたADP−リボシル化トキシンのAおよびBサブユニットの整列に基づく。
バイオ接着剤およびムコ接着剤も本発明でアジュバントとして用いることができる。適当なバイオ接着剤はエステル化ヒアルロン酸マイクロスフィア(Singh et al.(2001) J.Cont.Rele.70:267−276)またはポリ(アクリル酸)、ポリビニルアルコール、ポリビニルピロリドン、多糖およびカルボキシメチルセルロースの架橋誘導体のようなムコ接着剤を含む。キトサンおよびその誘導体も本発明でアジュバントとして用いることができる。例えば、WO 99/27960参照。
ミクロ粒子も本発明でアジュバントとして用いることができる。生分解性であって、非毒性である材料(例えば、ポリ(ラクチド−コ−グリコリドと共にポリ(α−ヒドロキシ酸)、ポリヒドロキシ酪酸、ポリオルトエステル、ポリアンヒドリド、ポリカプロラクトンなど)から形成されたミクロ粒子(直径が〜100nmないし〜150μm、より好ましくは直径が〜200nmないし〜30μm、最も好ましくは直径が〜500nmないし〜10μmの粒子)が好ましく、これは、所望により、(例えば、SDSで)負に荷電した表面または(例えば、CTABのようなカチオン洗剤で)正に荷電した表面を有するように処理されている。
アジュバントとして用いるのに適したリポソーム処方の例は米国特許第6,090,406号、米国特許第5,916,588号およびEP 0 626 169に記載されている。
本発明で用いるのに適したアジュバントはポリオキシエチレンエーテルおよびポリオキシエチレンエステルを含む。WO 99/52549。そのような処方は、さらに、オクトキシノール(WO 01/21207)と組み合わせたポリオキシエチレンソルビタンエステル界面活性剤ならびにオクトキシノール(WO 01/21152)のような少なくとも1つのさらなるノニオン性界面活性剤と組み合わせたポリオキシエチレンアルキルエーテルまたはエステル界面活性剤を含む。
PCPP処方は、例えば、Andrianov et al.,「Preparation of hydrogel microspheres by coacervation of aqueous polyphophazene solutions」, Biomaterials (1998) 19(1−3):109−115およびPayne et al.,「Protein Release from Polyphosphazene Matrices」, Adv.Drug.Derivery Review (1998) 31(3):185−196に記載されている。
本発明でアジュバントとして用いるのに適したムラミルペプチドの例はN−アセチル−ムラミル−N−スレオニル−D−イソグルタミン (thr−MDP)、N−アセチル−ノルムラミル−1−アラニル−d−イソグルタミン (nor−MDP)、およびN−アセチルムラミル−1−アラニル−d−イソグルタミニル−1−アラニン−2−(1’−2’−ジパルミトイル−sn−グリセロ−3−ヒドロキシホスホリルオキシ)−エチルアミン (MTP−PE)を含む。
本発明でアジュバントとして用いるのに適したイミダゾキノロン化合物の例は、さらに、Stanley, 「Imiquimod and the imidazoquinolones:mechanism of action and therapeutic potential」 Clin Exp Dermatol (2002) 27(7):571−577およびJones, 「Resiquimod 3M」, Curr Opin Investig Drugs (2003) 4(2):214−218に記載されたImiquiamodおよびそのホモログを含む。
(1)サポニンおよび水中油型エマルジョン(WO 99/11241);
(2)サポニン(例えば、QS21)+非毒性LPS誘導体(例えば、3dMPL)(WO 94/00153参照);
(3)サポニン(例えば、QS21)+非毒性LPS誘導体(例えば、3dMPL)+コレステロール;
(4)サポニン(例えば、QS21)+3dMPL+IL−12(所望により+ステロール)(WO 98/57659);
(5)例えば、QS21および/または水中油型エマルジョンと3dMPLとの組合せ(欧州特許出願0835318、0735898および0761231参照);
(6)サブミクロンエマルジョンにミクロ液化された、または攪拌してより大きな粒子サイズエマルジョンを生じさせた、10%スクアラン、0.4%Tween 80、5%プルロニック−ブロックポリマーL121およびTHR−MDPを含有するSAF;
(7)2%スクアレン、0.2%Tween 80、およびモノホスホリルリピドA(MPL)、トレハロースジムコレート(TDM)、および細胞壁骨格(CWS)、好ましくはMPL+CWS(DetoxTM)よりなる群から選択される1以上の細菌細胞壁成分を含有するRibiTMアジュバント系(RAS)(Ribi Immunochem);
(8)(アルミニウム塩のような)1以上のミネラル塩+(3dPMLのような)LPSの非毒性誘導体;および
(9)(アルミニウム塩のような)1以上のミネラル塩+(CpGモチーフを含むヌクレオチド配列のような)免疫刺激オリゴヌクレオチド。
本発明においてアジュバントとして用いるのに適したヒト免疫モジュレーターはインターロイキン(例えば、IL−1、IL−2、IL−4、IL−5、IL−6、IL−7、IL−12など)、インターフェロン(例えば、インターフェロン−γ)、マクロファージコロニー刺激因子、および腫瘍壊死因子のようなサイトカインを含む。
本発明の組成物は、さらに、Chlamydia trachomatisに加えて1以上の性的に伝播される病気に由来する抗原を含むことができる。好ましくは、該抗原は以下の性的に伝播する病気の1以上に由来する:N. gonorrhoeae (例えば、WO 99/24578、WO 99/36544、WO 99/57280、WO 02/079243);ヒトパピローマウイルス;Treponema pallidum;単純疱疹ウイルス(HSV−1またはHSV−2);HIV(HIV−1またはHIV−2);およびHaemophilus ducreyi。
表1(a)および1(b)のウェスタンブロット、FACSおよびインビトロ中和アッセイおよび分析をさらにこの実施例で考察する。材料の調製およびこれらのアッセイの詳細を以下に記載する。
表1(b)は、17のChlamidia trachomatis組換え融合タンパク質の組に対して生起された血清から得られたFACS結果を供し、これらは:CT016、CT017、CT043、CT082、CT153、CT262、CT276、CT296、CT372、CT398、CT548、CT043、CT635、CT671(全て仮想タンパク質)である。CT412(推定外側膜タンパク質)、CT480(オリゴペプチド結合タンパク質)、CT859(メタロプロテアーゼ)、CT089(低カルシウム応答エレメント−LcrE)、CT812(PmpD)およびCT869(PmpE)。FACS分析はHIS融合および/またはGST融合いずれかについて行った。これらのCT組換え融合タンパク質の全ては8.0よりも高いK−Sスコアを示し、FACS陽性と見なされた。CT398、CT372およびCT548を例外として、これらの仮想タンパク質の少なくともいずれも以前にはFACS陽性とは報告されていない。加えて、以下のタンパク質:CT050(仮想)、CT165(仮想)、CT711(仮想)およびCT552(仮想)もまた8.0よりも高いK−Sスコアを示し、FACS陽性と見なされた。これらの4つのタンパク質のいずれも以前にはFACS陽性と報告されていなかった。これらの仮想 CT抗原のいずれも、一般には、CT特異的抗原とみなされ、C.pneumoniaeカウンターパートを有しない。
以下の実施例は、マウスモデル内での第二、第三および第五抗原群からのCT抗原の種々の組合わせでの免疫化を説明する。具体的には、本実施例においては、第二の抗原群からの2つの抗原(CT242およびCT316)の組合せ、および、各々、第三の抗原群からの1つの抗原および第五の抗原群からの1つの抗原(CT812およびCT082)の組合わせでの免疫化が示される。
以下の実施例は、マウスモデル内での、第一の抗原群からのCT抗原の種々の組合せでの免疫化を示す。具体的には、この実施例では、第一の抗原群からの5つの抗原(CT045、CT381、CT396、CT398およびCT089)の組合せでの免疫化を示す。
(表3:実施例4についての免疫化スケジュール)
以下の実施例は、マウスモデル内での、第一の抗原群からのCT抗原の種々の組合せでの免疫化を説明する。具体的には、この実施例においては、第一の抗原群からの5つの抗原(CT045、CT381、CT396、CT398およびCT089)の組合せでの免疫化を示す。
他の細菌病原体について有望な結果を与えた新しいワクチン候補の同定を狙ったゲノム戦略に従って、我々は、組換え融合タンパク質として、C. trachomatisゲノムからin silico選択され、末梢に位置するタンパク質をコードするらしい158ORFをE.coliで発現させた。これらのタンパク質に対するポリクローナル抗体がマウスで生起され、平行スクリーニングにおいて、(i)(FACS−陽性血清および対応する抗原を同定する)フローサイトメトリーアッセイにおいて精製されたクラミジアに結合するそれらの能力、および(ii)インビトロ細胞培養(中和血清および抗原)についてのクラミジア感染性の>50%阻害を誘導するそれらの能力につき評価した。E.coliタンパク質抽出物への吸着によって部分的に精製された抗血清の特異性は、C. trachomatisのグラジエント−精製エレメンタリーボディのタンパク質抽出物に対してテストされた1:400希釈された血清(FACSアッセイスクリーニングにとって最適であることが見出されたのと同一希釈)のウェスタンブロット分析によって評価した。ウェスタンブロットの結果は、30のFACS陽性および/または中和抗血清の大部分が予測された分子サイズのいずれかの単一タンパク質バンドを認識し、あるいは予測されたクラミジア抗原と合致するバンドがいずれにしてもWBプロフィールにおいて圧倒的であることを示し、異なるサイズの従たるバンドがあるに過ぎなかった。事実、5つの抗原についてのみ、抗血清の真実の特異性に関して疑いが残り、すなわち、CT547タンパク質の場合には、予期されたバンドが存在したが支配的ではなく、WBがそれにつき得られた4つの場合は完全にブランクであった(CT456、CT476−AtoS、およびpmpD(CT812)およびpmpE(CT869)についての2つの融合タンパク質)。
本発明は、CT抗原の組合せがクラミジア攻撃に対して保護的であることを証明する。これらのCT抗原性組合せは、クラミジアへの暴露に際して迅速に応答することができる(中和抗体の点で)抗体応答および(少なくともTh1細胞プロフィールの点で)細胞媒介免疫応答の双方を誘導することができる。
Claims (25)
- Chlamydia trachomatis抗原の組合せを含有する免疫原性組成物であって、該組合せが、第一の抗原群の2個、3個、4個または5個全てのChlamydia trachomatis抗原からなり、該第一の抗原群がPepA、LcrE、ArtJ、DnaKおよびCT398からなる、組成物。
- 前記組合せが、PepA、LcrE、ArtJ、DnaKおよびCT398からなる、請求項1に記載の組成物。
- 前記組合せが、LcrEを含む、請求項1に記載の組成物。
- 前記組成物が、1種以上の免疫調節剤をさらに含有する、請求項1に記載の組成物。
- 前記1種以上の免疫調節剤が、アジュバントを含む、請求項4に記載の組成物。
- 前記アジュバントが、TH1アジュバントおよびTH2アジュバントからなる群より選択される、請求項5に記載の組成物。
- 前記アジュバントが、アルミニウム塩およびCpGモチーフを含むオリゴヌクレオチドからなる群より選択される、請求項5に記載の組成物。
- Chlamydia trachomatis抗原の組合せを含有する免疫原性組成物であって、該組合せは、第二の抗原群の2個、3個、4個、5個、6個、7個、8個、9個、10個、11個、12個または13個のChlamydia trachomatis抗原からなり、該第二の抗原群はPepA、LcrE、ArtJ、DnaK、CT398、OmpH−様、L7/L12、OmcA、AtoS、CT547、エノラーゼ、HtrAおよびMurGからなる、免疫原性組成物。
- 前記組合せが、PepA、LcrE、ArtJ、DnaK、OmpH−様およびCT398からなる群の1以上を含む、請求項8に記載の免疫原性組成物。
- 前記組合せが、LcrEを含む、請求項8に記載の免疫原性組成物。
- 前記組合せが、OmpH−様タンパク質を含む、請求項8に記載の免疫原性組成物。
- 前記組成物が、1以上の免疫調節剤をさらに含有する、請求項8に記載の組成物。
- 前記1以上の免疫調節剤が、アジュバントを含む、請求項12に記載の組成物。
- 前記アジュバントが、TH1アジュバントおよびTH2アジュバントからなる群より選択される、請求項13に記載の組成物。
- 前記アジュバントが、アルミニウム塩およびCpGモチーフを含むオリゴヌクレオチドからなる群より選択される、請求項13に記載の組成物。
- 請求項1〜15のいずれか1項に記載の免疫原性組成物を含むワクチン。
- Chlamydia trachomatis感染の予防または治療のための医薬の調製における、請求項1〜15のいずれか1項に記載の免疫原性組成物または請求項16に記載のワクチンの使用。
- 哺乳動物においてChlamydia trachomatis感染を中和する方法であって、該方法は、請求項1〜15いずれか1項に記載の組成物、または請求項16に記載のワクチン、または請求項1〜15のいずれか1項に定義される免疫原性組成物を認識する抗体の有効量を該哺乳動物に投与する工程を包含する、方法。
- Chlamydia trachomatis感染に対して哺乳動物において免疫応答を惹起させる方法であって、該方法は、請求項1〜15のいずれか1項に記載の組成物、または請求項16に記載のワクチン、または請求項1〜15のいずれか1項に定義される免疫原性組成物を認識する抗体の有効量を該哺乳動物に投与する工程を包含する、方法。
- 前記組成物が、増強されたTH1免疫応答およびTH2免疫応答を誘発する、請求項19に記載の方法。
- Chlamydia trachomatis特異的抗体を惹起する方法であって、該方法は、請求項1〜15のいずれか1項に記載の組成物、または請求項16に記載のワクチン、または請求項1〜15のいずれか1項に定義されるタンパク質を認識する抗体の有効量を哺乳動物に投与する工程を包含する、方法。
- Chlamydia trachomatis抗原の組合せを含有する免疫原性組成物であって、該組合せは、第一の抗原群の2個、3個、4個または5個全てのChlamydia trachomatis抗原からなり、該第一の抗原群は、PepA、LcrE、ArtJ、DnaKおよびCT398からなり、ここで、該組成物は、1種以上の免疫調節剤をさらに含有する、免疫原性組成物。
- CpGモチーフを含むオリゴヌクレオチド、ミネラル塩、および性的に伝播する疾患に関連する抗原を含有する、免疫原性組成物。
- 前記ミネラル塩が、アルミニウム塩である、請求項23に記載の組成物。
- 前記抗原が、Chlamydia trachomatis抗原である、請求項23に記載の組成物。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0315020.8 | 2003-06-26 | ||
GB0315020A GB0315020D0 (en) | 2003-06-26 | 2003-06-26 | Immunogenic compositions for chlamydia trachomatis |
US49764903P | 2003-08-25 | 2003-08-25 | |
US60/497,649 | 2003-08-25 | ||
GB0402236.4 | 2004-02-02 | ||
GB0402236A GB0402236D0 (en) | 2004-02-02 | 2004-02-02 | Immunogenic compositions for chlamydia trachomatis |
US57637504P | 2004-06-01 | 2004-06-01 | |
US60/576,375 | 2004-06-01 | ||
PCT/US2004/020491 WO2005002619A2 (en) | 2003-06-26 | 2004-06-25 | Immunogenic compositions for chlamydia trachomatis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007535473A true JP2007535473A (ja) | 2007-12-06 |
JP4896715B2 JP4896715B2 (ja) | 2012-03-14 |
Family
ID=45907997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006517684A Expired - Fee Related JP4896715B2 (ja) | 2003-06-26 | 2004-06-25 | Chlamydiatrachomatisに対する免疫原性組成物 |
Country Status (9)
Country | Link |
---|---|
US (4) | US20100255002A1 (ja) |
EP (1) | EP1635865A2 (ja) |
JP (1) | JP4896715B2 (ja) |
CN (1) | CN1812809A (ja) |
BR (1) | BRPI0411857A (ja) |
CA (1) | CA2526106A1 (ja) |
MX (1) | MXPA05013260A (ja) |
RU (1) | RU2352356C2 (ja) |
WO (1) | WO2005002619A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008520550A (ja) * | 2004-10-25 | 2008-06-19 | ステーテンズ セーラム インスティテュート | クラミジア・トラコマチス(Chlamydiatrachomatis)抗原のワクチンおよび診断への使用 |
JP2013545448A (ja) * | 2010-10-20 | 2013-12-26 | ジェノセア バイオサイエンシーズ, インコーポレイテッド | クラミジア抗原及びその使用 |
JP2020090445A (ja) * | 2018-12-04 | 2020-06-11 | 国立大学法人大阪大学 | 免疫賦活剤 |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080213264A1 (en) * | 1998-12-08 | 2008-09-04 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
US6919187B2 (en) * | 2000-04-21 | 2005-07-19 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
WO2004074318A2 (en) * | 2003-02-24 | 2004-09-02 | Institut Pasteur | Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof. |
JP4896715B2 (ja) * | 2003-06-26 | 2012-03-14 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Chlamydiatrachomatisに対する免疫原性組成物 |
JP2008504292A (ja) | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | 免疫増強用の化合物 |
WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
US20080260763A1 (en) * | 2004-07-01 | 2008-10-23 | The Regents Of The University Of California | High Throughput Proteomics |
CA2575548A1 (en) | 2004-07-29 | 2006-07-27 | John L. Telford | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
WO2006089264A2 (en) | 2005-02-18 | 2006-08-24 | Novartis Vaccines And Diagnostics Inc. | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
CN101203529A (zh) | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸 |
US8541007B2 (en) | 2005-03-31 | 2013-09-24 | Glaxosmithkline Biologicals S.A. | Vaccines against chlamydial infection |
EP2392348A3 (en) * | 2005-03-31 | 2012-01-18 | GlaxoSmithKline Biologicals S.A. | Vaccines against chlamydial infection |
CN101238146A (zh) | 2005-05-12 | 2008-08-06 | 诺华疫苗和诊断有限公司 | 砂眼衣原体的免疫原性组合物 |
WO2006128296A1 (en) * | 2005-06-01 | 2006-12-07 | Sanofi Pasteur Limited | Pal-based chlamydia vaccine |
WO2007030879A1 (en) * | 2005-09-13 | 2007-03-22 | Diatech Pty Ltd | Diagnostic markers and uses therefor |
US20110223197A1 (en) | 2005-10-18 | 2011-09-15 | Novartis Vaccines And Diagnostics Inc. | Mucosal and Systemic Immunization with Alphavirus Replicon Particles |
CA2630220C (en) | 2005-11-22 | 2020-10-13 | Doris Coit | Norovirus and sapovirus antigens |
AU2006341122B2 (en) * | 2005-12-22 | 2013-08-22 | Novartis Vaccines And Diagnostics, Srl. | Chlamydial antigens |
WO2007082105A2 (en) * | 2006-01-16 | 2007-07-19 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chlamydia vaccine |
EP2368570A3 (en) | 2006-01-18 | 2012-05-02 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
EP2064230A2 (en) | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogens from uropathogenic escherichia coli |
JP5580047B2 (ja) * | 2006-10-13 | 2014-08-27 | バイオテック ツールズ エスエー | DnaKの精製方法 |
CN101528771B (zh) | 2006-10-13 | 2013-10-30 | 生物技术工具公司 | 纯化dnak的方法 |
WO2008140478A2 (en) * | 2006-11-01 | 2008-11-20 | Immport Therapeutics, Inc. | Compositions and methods for immunodominant antigens |
EP2517725A1 (en) | 2007-05-01 | 2012-10-31 | Board Of Regents, The University Of Texas | Chlamydial antigens as reagents for diagnosis and treatment of chlamydial infection and disease |
US20110027321A1 (en) * | 2007-05-25 | 2011-02-03 | Emergent Product Development Gaithersburg Inc. | Chlamydia Vaccine Comprising HtrA Polypeptides |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
WO2009020553A2 (en) * | 2007-08-03 | 2009-02-12 | President And Fellows Of Harvard College | Chlamydia antigens |
CN101969992B (zh) | 2007-09-12 | 2014-10-01 | 诺华股份有限公司 | Gas57突变型抗原和gas57抗体 |
US7892567B2 (en) * | 2007-10-01 | 2011-02-22 | Board Of Regents, The University Of Texas System | Methods and compositions for immunization against chlamydial infection and disease |
CN104292312A (zh) | 2007-12-21 | 2015-01-21 | 诺华股份有限公司 | 链球菌溶血素o的突变形式 |
WO2009111337A1 (en) | 2008-03-03 | 2009-09-11 | Irm Llc | Compounds and compositions as tlr activity modulators |
US20110236489A1 (en) | 2008-09-18 | 2011-09-29 | Novartis Ag | Vaccine adjuvant combinations |
WO2010042206A1 (en) * | 2008-10-09 | 2010-04-15 | Board Of Regents, University Of Texas System | Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease |
WO2010068413A1 (en) * | 2008-11-25 | 2010-06-17 | Emergent Product Development Gaithersburg Inc. | Chlamydia vaccine comprising htra polypeptides |
US8585505B2 (en) | 2008-12-15 | 2013-11-19 | Tetris Online, Inc. | Inter-game interactive hybrid asynchronous computer game infrastructure |
JP2012515157A (ja) | 2009-01-12 | 2012-07-05 | ノバルティス アーゲー | グラム陽性細菌に対するワクチンにおけるCna_Bドメイン抗原 |
EP2413959A4 (en) * | 2009-01-29 | 2013-06-19 | British Columbia Cancer Agency | CHLAMYDIA-ANTIGENE COMPREHENSIVE COMPOSITIONS |
EP2403526B1 (en) * | 2009-03-06 | 2019-05-15 | GlaxoSmithKline Biologicals SA | Chlamydia antigens |
WO2010135704A2 (en) * | 2009-05-22 | 2010-11-25 | Institute For Systems Biology | Secretion-related bacterial proteins for nlrc4 stimulation |
ITMI20090946A1 (it) | 2009-05-28 | 2010-11-29 | Novartis Ag | Espressione di proteine ricombinanti |
AU2010258677B2 (en) | 2009-06-10 | 2016-10-06 | Glaxosmithkline Biologicals S.A. | Benzonaphthyridine-containing vaccines |
EP2443250B8 (en) | 2009-06-16 | 2016-09-21 | GlaxoSmithKline Biologicals SA | High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays |
WO2011024071A1 (en) | 2009-08-27 | 2011-03-03 | Novartis Ag | Adjuvant comprising aluminium, oligonucleotide and polycation |
WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
DK2459216T3 (da) | 2009-09-02 | 2013-12-09 | Novartis Ag | Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer |
WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
SG10201501980SA (en) | 2009-12-15 | 2015-05-28 | Novartis Ag | Homogeneous suspension of immunopotentiating compounds and uses thereof |
ES2707778T3 (es) | 2009-12-30 | 2019-04-05 | Glaxosmithkline Biologicals Sa | Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli |
CA2792938C (en) | 2010-03-23 | 2018-07-31 | Irm Llc | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
US9322827B2 (en) | 2010-04-08 | 2016-04-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | B-cell antigen presenting cell assay |
EP4180057A1 (en) | 2010-07-06 | 2023-05-17 | GlaxoSmithKline Biologicals S.A. | Virion-like delivery particles for self-replicating rna molecules |
EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
ES2770335T3 (es) | 2010-07-06 | 2020-07-01 | Glaxosmithkline Biologicals Sa | Administración de ARN para desencadenar múltiples vías inmunológicas |
US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
AU2011295935B2 (en) | 2010-08-31 | 2016-02-11 | Glaxosmithkline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding RNA |
ES2727583T3 (es) | 2010-08-31 | 2019-10-17 | Glaxosmithkline Biologicals Sa | Lípidos adecuados para la administración liposómica de ARN que codifica proteínas |
ES2458355T3 (es) | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorción de inmunopotenciadores sobre sales metálicas insolubles |
KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
ES2630029T3 (es) | 2010-12-14 | 2017-08-17 | Glaxosmithkline Biologicals Sa | Análisis de citometría de flujo de materiales adsorbidos en sales metálicas |
EP2667852B1 (en) | 2011-01-27 | 2016-11-09 | GlaxoSmithKline Biologicals SA | Adjuvant nanoemulsions with crystallisation inhibitors |
BR112013022397A2 (pt) | 2011-03-02 | 2017-09-26 | Derek OHagan | vacinas combinadas com doses menores de antígeno e/ou adjuvante |
ES2785108T3 (es) | 2011-03-24 | 2020-10-05 | Glaxosmithkline Biologicals Sa | Nanoemulsiones adyuvantes con fosfolípidos |
SG10201605537XA (en) | 2011-07-06 | 2016-09-29 | Novartis Ag | Liposomes having useful n:p ratio for delivery of rna molecules |
JP2014522842A (ja) | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
LT2750707T (lt) | 2011-08-31 | 2019-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Streptococcuspneumoniae抗原の増強された製剤 |
SI2822947T1 (sl) | 2012-03-07 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Argininske soli TLR7 agonista |
JP6345603B2 (ja) | 2012-03-08 | 2018-06-20 | ノバルティス アーゲー | 追加免疫ワクチンのアジュバント化された処方物 |
RU2662970C2 (ru) | 2012-09-18 | 2018-07-31 | Новартис Аг | Везикулы наружной мембраны |
BR112015007126A2 (pt) | 2012-10-02 | 2017-08-08 | Glaxosmithkline Biologicals Sa | composição, método para induzir uma resposta imune, e, uso de uma composição |
WO2014118305A1 (en) | 2013-02-01 | 2014-08-07 | Novartis Ag | Intradermal delivery of immunological compositions comprising toll-like receptor agonists |
EA030650B1 (ru) | 2013-03-08 | 2018-09-28 | Новартис Аг | Липиды и липидные композиции для доставки активных агентов |
RU2723046C2 (ru) * | 2013-03-18 | 2020-06-08 | Статенс Серум Институт | Вакцины против Chlamydia sp. |
BR112016012306A2 (pt) | 2013-12-03 | 2017-09-26 | Swiss Tropical And Public Health Inst | peptídeos ricos em prolina para proteção contra s. pneumoniae |
PL3083556T3 (pl) | 2013-12-19 | 2020-06-29 | Novartis Ag | Lipidy i kompozycje lipidowe dla dostarczania środków czynnych |
EP4019506A1 (en) | 2013-12-19 | 2022-06-29 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
US10835594B2 (en) | 2014-01-16 | 2020-11-17 | Mcmaster University | Type III secretion injectisome proteins for treatment and prevention of chlamydial infections |
US10342761B2 (en) | 2014-07-16 | 2019-07-09 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
EP3188760B1 (en) | 2014-09-05 | 2023-12-06 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
US10596247B2 (en) | 2015-02-20 | 2020-03-24 | Board Of Regents, The University Of Texas System | Methods and compositions for attenuated chlamydia as vaccine and vector |
EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
US10962534B2 (en) | 2016-02-22 | 2021-03-30 | Boehringer Ingelheim Vetmedica Gmbh | Method for the immobilization of biomolecules |
JP2020526567A (ja) * | 2017-07-13 | 2020-08-31 | ナノビオ コーポレイションNanobio Corporation | クラミジアナノエマルジョンワクチン |
CA3090271A1 (en) | 2018-02-12 | 2019-08-15 | Inimmune Corporation | Toll-like receptor ligands |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
WO2020176700A1 (en) * | 2019-02-27 | 2020-09-03 | Yale University | Compositions and methods for enhancing mucosal immunity |
CN110699364B (zh) * | 2019-10-30 | 2021-05-28 | 广西大学 | 一种负向调控十字花科黑腐病菌三型分泌***的基因 |
CN111748021B (zh) * | 2020-06-09 | 2021-09-07 | 温州医科大学 | 一种对沙眼衣原体momp具有结合亲和力的多肽及其应用 |
CN111920946B (zh) * | 2020-08-07 | 2021-05-28 | 合肥诺为尔基因科技服务有限公司 | 环二核苷酸修饰铝纳米粒疫苗佐剂-传递***及基于其的SARS-CoV-2亚单位疫苗 |
CA3198924A1 (en) | 2020-11-04 | 2022-05-12 | Eligo Bioscience | Phage-derived particles for in situ delivery of dna payload into c. acnes population |
EP4032545A1 (en) * | 2021-01-26 | 2022-07-27 | Medizinische Hochschule Hannover | Immunogenic composition and vaccine containing chlamydia ssp. surface antigens and its use |
CA3209251A1 (en) * | 2021-01-29 | 2022-08-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes |
WO2023021427A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
CN113567665A (zh) * | 2021-08-16 | 2021-10-29 | 固安林科特生物工程有限公司 | 一种用于沙眼衣原体抗原检测的裂解液及检测方法 |
EP4387596A1 (en) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003049762A2 (en) * | 2001-12-12 | 2003-06-19 | Chiron Srl. | Immunisation against chlamydia trachomatis |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770714A (en) * | 1985-01-14 | 1998-06-23 | Washington Research Foundation | Chlamydia major outer membrane protein |
US20030219453A1 (en) * | 1998-03-19 | 2003-11-27 | Smithkline Beecham Biologicals, Sa | Vaccines |
US7041490B1 (en) * | 1997-11-28 | 2006-05-09 | Serono Genetics Institute, S.A. | Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same |
US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
US7731980B2 (en) * | 2000-10-02 | 2010-06-08 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
GB0203403D0 (en) * | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
JP4896715B2 (ja) * | 2003-06-26 | 2012-03-14 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Chlamydiatrachomatisに対する免疫原性組成物 |
DE10330981B4 (de) * | 2003-07-09 | 2010-04-01 | Medion Diagnostics Ag | Vorrichtung und Verfahren zur simultanen Durchführung von Blutgruppenbestimmung, Serumgegenprobe und Antikörpersuch-Test |
EP1807446A2 (en) * | 2004-10-08 | 2007-07-18 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic and therapeutic compositions for streptococcus pyogenes |
CN101238146A (zh) * | 2005-05-12 | 2008-08-06 | 诺华疫苗和诊断有限公司 | 砂眼衣原体的免疫原性组合物 |
AU2006341122B2 (en) * | 2005-12-22 | 2013-08-22 | Novartis Vaccines And Diagnostics, Srl. | Chlamydial antigens |
-
2004
- 2004-06-25 JP JP2006517684A patent/JP4896715B2/ja not_active Expired - Fee Related
- 2004-06-25 MX MXPA05013260A patent/MXPA05013260A/es not_active Application Discontinuation
- 2004-06-25 WO PCT/US2004/020491 patent/WO2005002619A2/en active Application Filing
- 2004-06-25 RU RU2006102143/13A patent/RU2352356C2/ru not_active IP Right Cessation
- 2004-06-25 US US10/561,236 patent/US20100255002A1/en not_active Abandoned
- 2004-06-25 BR BRPI0411857-0A patent/BRPI0411857A/pt not_active IP Right Cessation
- 2004-06-25 EP EP04756137A patent/EP1635865A2/en not_active Ceased
- 2004-06-25 CN CNA2004800179891A patent/CN1812809A/zh active Pending
- 2004-06-25 CA CA002526106A patent/CA2526106A1/en not_active Abandoned
- 2004-12-22 US US11/018,868 patent/US20060034871A1/en active Pending
-
2010
- 2010-10-01 US US12/896,353 patent/US20110070266A1/en not_active Abandoned
-
2013
- 2013-01-04 US US13/734,023 patent/US20130171238A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003049762A2 (en) * | 2001-12-12 | 2003-06-19 | Chiron Srl. | Immunisation against chlamydia trachomatis |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008520550A (ja) * | 2004-10-25 | 2008-06-19 | ステーテンズ セーラム インスティテュート | クラミジア・トラコマチス(Chlamydiatrachomatis)抗原のワクチンおよび診断への使用 |
JP2013545448A (ja) * | 2010-10-20 | 2013-12-26 | ジェノセア バイオサイエンシーズ, インコーポレイテッド | クラミジア抗原及びその使用 |
JP2020090445A (ja) * | 2018-12-04 | 2020-06-11 | 国立大学法人大阪大学 | 免疫賦活剤 |
JP7385206B2 (ja) | 2018-12-04 | 2023-11-22 | 国立大学法人大阪大学 | 免疫賦活剤 |
Also Published As
Publication number | Publication date |
---|---|
EP1635865A2 (en) | 2006-03-22 |
US20130171238A1 (en) | 2013-07-04 |
WO2005002619A2 (en) | 2005-01-13 |
US20060034871A1 (en) | 2006-02-16 |
RU2352356C2 (ru) | 2009-04-20 |
US20100255002A1 (en) | 2010-10-07 |
BRPI0411857A (pt) | 2006-05-23 |
WO2005002619A3 (en) | 2005-09-01 |
RU2006102143A (ru) | 2006-07-27 |
US20110070266A1 (en) | 2011-03-24 |
CN1812809A (zh) | 2006-08-02 |
MXPA05013260A (es) | 2006-03-09 |
CA2526106A1 (en) | 2005-01-13 |
JP4896715B2 (ja) | 2012-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4896715B2 (ja) | Chlamydiatrachomatisに対する免疫原性組成物 | |
US8133973B2 (en) | Immunogenic compositions for Chlamydia trachomatis | |
US8481057B2 (en) | Chlamydial antigens | |
JP5219803B2 (ja) | グラム陽性菌の血清耐性因子 | |
JP2007526318A (ja) | Chlamydiapneumoniaeに対する免疫原性組成物 | |
EP1954306A2 (en) | Compositions comprising yersinia pestis antigens | |
MX2007012108A (es) | Vacunas contra infeccion por chlamydia. | |
JP2012501959A (ja) | Yersiniapestis抗原を含む組成物 | |
CA2803061A1 (en) | Vaccines and compositions against streptococcus pneumoniae | |
JP2014503002A (ja) | 肺炎連鎖球菌(Streptococcuspneumoniae)に対するワクチン及び組成物 | |
JP2013520487A (ja) | 免疫原性タンパク質および組成物 | |
JP2012519482A (ja) | クラミジア抗原 | |
JP2010505795A (ja) | クラミジア感染症に対するワクチン | |
US8541007B2 (en) | Vaccines against chlamydial infection | |
RU2335505C2 (ru) | Белок nmb0928 и его применение в фармацевтических композициях | |
AU2012261545A1 (en) | Immunogenic compositions for Chlamydia trachomatis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081211 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100615 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100913 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100921 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101013 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101020 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110325 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110621 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110628 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110722 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110922 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111201 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111221 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150106 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |